spacer
home > > autumn 2003 > new approaches to developing cancer drugs
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement